Serious but rare adverse effects include: Acute pancreatitis (patients should be advised to seek immediate medical attention for severe, persistent abdominal pain) Gallbladder disease, including cholecystitis and cholelithiasis Acute kidney injury, particularly in the context of dehydration from gastrointestinal side effects Hypoglycaemia, especially when used alongside other glucose-lowering medications Thyroid C-cell tumours (observed in rodent studies
Cota D, Matter EK, Woods SC, Seeley RJ
Optimal acquisition and modeling parameters for accurate assessment of low K trans bloodbrain barrier permeability using dynamic contrast-enhanced MRI
A small pilot study in nondiabetic subjects at cardiovascular risk found that one gram of ALCAR twice daily for 24 weeks improved glucose disposal rates in those who were most insulin-resistant at baseline
Clinical features Melanocytic nevi first appear in early childhood and increase in number during the second and third decades
Clinical trials demonstrate a clear dose-response relationship, with higher doses producing greater HbA1c reductions and weight loss